drugset

drugset / Trial / NCT03282344

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03282344 ↗

Phase 2 Active not recruiting 88 enrolled Memorial Sloan Kettering Cancer Center M.D. Anderson Cancer Center · collab Rockefeller University · collab Stanford University · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.

Timeline

Start: 2017-09-12
Primary completion: 2026-09
Completion: 2026-09

Publications

D'Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022 Jun 16;13(1):3477. doi: 10.1038/s41467-022-30874-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bempegaldesleukin	Protein / enzyme biologic	0.006 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	360 mg	Intravenous

Indications